The ESPRIT trial focused on intensive blood pressure lowering to a systolic target below 120 mm Hg compared to standard treatment targeting below 140 mm Hg. Lead investigator Jing Li reported a 12% lower incidence of major vascular events, 39% lower cardiovascular mortality, and 21% lower all-cause mortality with intensive treatment. The trial included high-risk individuals, including those with diabetes and a history of stroke, showing benefits extended to these groups. Results indicated the prevention of 14 major vascular events and eight deaths per 1000 individuals treated for 3 years. The trial highlighted the potential to save lives and reduce heart disease burden globally. The study was presented at the AHA Scientific Sessions 2023, involving 11,255 Chinese adults with baseline systolic blood pressure measurements. The primary outcome showed a 12% reduction in events with intensive treatment, with positive trends in individual endpoints. Serious adverse events included an increase in syncope in the intensive group.
Para outro idioma
do conteúdo fonte
www.medscape.com
Principais Insights Extraídos De
by Sue Hughes às www.medscape.com 11-16-2023
https://www.medscape.com/viewarticle/998564Perguntas Mais Profundas